Icosavax Company
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Investors
Founded Date:
2017-01-01
Total Funding:
161000000.0
Employee Number:
11-50
Funding Status:
IPO
Last Funding Type:
Series B
Investors Number:
15.0
Last Funding Date:
2021-04-07
Industry:
End-to-End Drug Development
Headquarters:
Seattle, Washington, United States
Estimated Revenue:
$10M to $50M